These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 26017508

  • 1. Onabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experience.
    Grazzi L, Usai S.
    Neurol Sci; 2015 May; 36 Suppl 1():33-5. PubMed ID: 26017508
    [Abstract] [Full Text] [Related]

  • 2. The use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.
    Russo M, Manzoni GC, Taga A, Genovese A, Veronesi L, Pasquarella C, Sansebastiano GE, Torelli P.
    Neurol Sci; 2016 Jul; 37(7):1127-31. PubMed ID: 27048312
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse.
    Grazzi L, Usai S.
    Neurol Sci; 2014 May; 35 Suppl 1():37-9. PubMed ID: 24867833
    [Abstract] [Full Text] [Related]

  • 4. Onabotulinum toxin A for treatment of chronic migraine with medication overuse.
    Grazzi L.
    Neurol Sci; 2013 May; 34 Suppl 1():S27-8. PubMed ID: 23695040
    [Abstract] [Full Text] [Related]

  • 5. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
    Kollewe K, Escher CM, Wulff DU, Fathi D, Paracka L, Mohammadi B, Karst M, Dressler D.
    J Neural Transm (Vienna); 2016 May; 123(5):533-40. PubMed ID: 27032774
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B, Gaul C, Martelletti P, García-Moncó JC, Brown S.
    J Headache Pain; 2017 Sep 06; 18(1):93. PubMed ID: 28879545
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A?
    Butera C, Colombo B, Bianchi F, Cursi M, Messina R, Amadio S, Guerriero R, Comi G, Del Carro U.
    Neurol Sci; 2016 Oct 06; 37(10):1701-6. PubMed ID: 27395386
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P, REPOSE Principal Investigators.
    J Headache Pain; 2019 Mar 07; 20(1):26. PubMed ID: 30845917
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.